Association between Inhaled β₂-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study

References

• GINA. Global initiative for Asthma; 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed December 29, 2020.
   Google Scholar
• GOLD. COPD gold guidelines; 2020. Available from: https://goldcopd.org/wp-content/uploads/2020/03/GOLD-2020-POCKET-GUIDE-ver1.0_FINAL-WMV.pdf. Accessed December 30, 2020.
   Google Scholar
• Barisione G, Baroffio M, Crimi E, et al. Beta-adrenergic agonists. Pharmaceuticals. 2010;3(4):1016–1044. doi:10.3390/ph3041016
   Google Scholar
• Abosamak NER, Shahin MH. Beta 2 receptor agonists/ antagonists. In: StatPearls. Treasure Island FL: StatPearls Publishing LLC; 2021.
   Google Scholar
• Cazzola M, Page CP, Rogliani P, et al. β 2 -agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187(7):690–696. doi:10.1164/rccm.201209-1739PP
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Tremor and β(2)-adrenergic agents: is it a real clinical problem? Pulm Pharmacol Ther. 2012;25(1):4–10. doi:10.1016/j.pupt.2011.12.004
   PubMed Web of Science ®Google Scholar
• Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002;110(6 Suppl):S322–S328. doi:10.1067/mai.2002.129966
   PubMedGoogle Scholar
• Taylor DR, Sears MR, Cockcroft DW. The beta-agonist controversy. Med Clin North Am. 1996;80(4):719–748. doi:10.1016/S0025-7125(05)70465-X
   PubMed Web of Science ®Google Scholar
• Billington CK, Penn RB, Hall IP. β(2) agonists. Handb Exp Pharmacol. 2017;237:23–40.
   PubMedGoogle Scholar
• Dong YH, Chang C-H, Gagne JJ, et al. Comparative cardiovascular and cerebrovascular safety of inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a Population-Based Cohort Study. Pharmacotherapy. 2016;36(1):26–37. doi:10.1002/phar.1684
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Xia N, Wang H, Nie X, Bhattacharya S. Inhaled long-acting β2-agonists do not increase fatal cardiovascular adverse events in COPD: a Meta-Analysis. PLoS One. 2015;10(9):e0137904. doi:10.1371/journal.pone.0137904
   PubMed Web of Science ®Google Scholar
• Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest. 2012;142(2):298–304. doi:10.1378/chest.10-2499
   PubMed Web of Science ®Google Scholar
• Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305–311. doi:10.1378/chest.11-1597
   PubMed Web of Science ®Google Scholar
• Juniper EF, O′byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:10.1034/j.1399-3003.1999.14d29.x
   PubMed Web of Science ®Google Scholar
• Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175–1185. doi:10.1001/jamainternmed.2013.1016
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging. 2004;21(6):405–414. doi:10.2165/00002512-200421060-00005
   PubMed Web of Science ®Google Scholar
• Tricco AC, Strifler L, Veroniki -A-A, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5(10):e009183. doi:10.1136/bmjopen-2015-009183
   PubMed Web of Science ®Google Scholar
• Lulich KM, Goldie RG, Ryan G, Paterson JW, et al. Adverse reactions to beta 2-agonist bronchodilators. Med Toxicol. 1986;1(4):286–299. doi:10.1007/BF03259844
   PubMedGoogle Scholar
• Lockett MF. Dangerous effects of isoprenaline in myocardial failurE. Lancet. 1965;2(7403):104–106. doi:10.1016/S0140-6736(65)92221-X
   PubMed Web of Science ®Google Scholar
• Busse WW, Bateman ED, Caplan AL, et al. Combined analysis of asthma safety trials of long-acting β(2)-agonists. N Engl J Med. 2018;378(26):2497–2505. doi:10.1056/NEJMoa1716868
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. doi:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• Quint JK, Moore E, Lewis A, et al. Recruitment of patients with Chronic Obstructive Pulmonary Disease (COPD) from the Clinical Practice Research Datalink (CPRD) for research. NPJ Prim Care Respir Med. 2018;28(1):21. doi:10.1038/s41533-018-0089-3
   PubMed Web of Science ®Google Scholar
• Hamilton W. Using CPRD data for public health research. Br J Gen Pract. 2018;68(672):334. doi:10.3399/bjgp18X697745
   PubMed Web of Science ®Google Scholar
• McDonald L, Schultze A, Carroll R, et al. Performing studies using the UK clinical practice research datalink: to link or not to link? Eur J Epidemiol. 2018;33(6):601–605. doi:10.1007/s10654-018-0389-5
   PubMed Web of Science ®Google Scholar
• Price DB, Carter V, Martin J, et al. Comparative safety profile of the fixed-dose combination corticosteroid and long-acting β(2)-agonist fluticasone propionate/formoterol fumarate: a 36-month longitudinal cohort study in UK primary care. Drugs. 2020;80(1):47–60. doi:10.1007/s40265-019-01224-8
   PubMed Web of Science ®Google Scholar
• Afonso A, Schmiedl S, Becker C, et al. A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction. Eur J Clin Pharmacol. 2016;72(9):1105–1116. doi:10.1007/s00228-016-2071-8
   PubMed Web of Science ®Google Scholar
• Amegadzie JE, Gamble J-M, Farrell J, et al. Gender differences in inhaled pharmacotherapy utilization in patients with Obstructive Airway Diseases (OADs): a Population-Based Study. Int J Chron Obstruct Pulmon Dis. 2020;15:2355–2366. doi:10.2147/COPD.S264580
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of initial LAMA versus LABA in COPD: real-World Cohort Study. COPD. 2021;18(1):1–8. doi:10.1080/15412555.2021.1877649
   PubMedGoogle Scholar
• Nissen F, Morales DR, Mullerova H, et al. Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open. 2017;7(8):e017474. doi:10.1136/bmjopen-2017-017474
   PubMed Web of Science ®Google Scholar
• Quint JK, Mullerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• Essebag V, Platt RW, Abrahamowicz M, et al. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5(1):5. doi:10.1186/1471-2288-5-5
   PubMedGoogle Scholar
• Suissa S. The Quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. Epidemiology. 2015;26(2):242–246. doi:10.1097/EDE.0000000000000221
   PubMed Web of Science ®Google Scholar
• Wu J, Ye Y, Li C, et al. Correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD: a Bayesian Network Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2019;74(3):255–265. doi:10.1097/FJC.0000000000000705
   PubMed Web of Science ®Google Scholar
• Li C, Cheng W, Guo J, et al. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Int J Chron Obstruct Pulmon Dis. 2019;14:799–808. doi:10.2147/COPD.S198288
   PubMed Web of Science ®Google Scholar
• Wang M-T, Liou J-T, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a Nested Case-Control Study. JAMA Intern Med. 2018;178(2):229–238. doi:10.1001/jamainternmed.2017.7720
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309–2321. doi:10.1378/chest.125.6.2309
   PubMed Web of Science ®Google Scholar
• Postma DS, Rabe KF. The Asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–1249. doi:10.1056/NEJMra1411863
   PubMed Web of Science ®Google Scholar
• Lee C-H, Choi S, Jang EJ, et al. Inhaled bronchodilators and the risk of tachyarrhythmias. Int J Cardiol. 2015;190:133–139. doi:10.1016/j.ijcard.2015.04.129
   PubMed Web of Science ®Google Scholar
• De Vries F, Pouwels S, Bracke M, et al. Use of β 2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol. 2008;65(4):580–586. doi:10.1111/j.1365-2125.2007.03077.x
   PubMed Web of Science ®Google Scholar
• Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax. 2003;58(1):43–46. doi:10.1136/thorax.58.1.43
   PubMed Web of Science ®Google Scholar
• Martin RM, Dunn NR, Freemantle SN, et al. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax. 1998;53(7):558–562. doi:10.1136/thx.53.7.558
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs. 2005;65(12):1595–1610. doi:10.2165/00003495-200565120-00001
   PubMed Web of Science ®Google Scholar
• Wood-Baker R, Cochrane B, Naughton MT. Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment. Intern Med J. 2010;40(2):94–101. doi:10.1111/j.1445-5994.2009.02109.x
   PubMed Web of Science ®Google Scholar
• Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59(3):297–309. doi:10.1161/01.RES.59.3.297
   PubMed Web of Science ®Google Scholar
• Kavelaars A, van de Pol M, Zijlstra J, Heijnen CJ. Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. J Neuroimmunol. 1997;77:211–216. doi:10.1016/S0165-5728(97)00076-3
   PubMed Web of Science ®Google Scholar
• Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease International. J Cardiol. 2008;124:319–325.
   Web of Science ®Google Scholar
• Panichi V, Taccola D, Rizza GM, et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract. 2006;102:c51–c58. doi:10.1159/000088923
   PubMedGoogle Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer J. Prognostic value of interleukin-8 as a predictor of heart failure in patients with myocardial infarction and percutaneous intervention. Int J Cardiol. 2006;111:158–160. doi:10.1016/j.ijcard.2005.05.063
   PubMed Web of Science ®Google Scholar
• Graham LN, Smith PA, Huggett RJ, Stoker JB, Mackintosh AF, Mary DA. Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction. Circulation. 2004;109:2285–2289. doi:10.1161/01.CIR.0000129252.96341.8B
   PubMed Web of Science ®Google Scholar
• Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913–919. doi:10.1161/01.CIR.73.5.913
   PubMed Web of Science ®Google Scholar
• Wada Y, Nakano S, Morimoto A, et al. Discovery of novel indazole derivatives as orally available β3-adrenergic receptor agonists lacking off-target-based cardiovascular side effects. J Med Chem. 2017;60(8):3252–3265. doi:10.1021/acs.jmedchem.6b01197
   PubMed Web of Science ®Google Scholar
• Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J. 1993;6(2):204–210.
   PubMed Web of Science ®Google Scholar